₹ 3.9 Cr
Volume Transacted
(Dec 20, 2024)
31.6 K
Stocks Traded
(Dec 20, 2024)
Last Updated on: Dec 22, 2024
Aurobindo Pharma Ltd
NSE: AUROPHARMA
ISIN
INE406A01037
Last updated on: Dec 22, 2024
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
Aurobindo Pharma Ltd
NSE: AUROPHARMA
Share Price
₹ 1240.7
-14.70 (-1.17%)
Last updated on: Dec 20, 2024
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
Date | Price (₹) | Day Open (₹) | Day High (₹) | Day Low (₹) |
---|
20 Dec 2024 | 1240.7 | 1254 | 1274.7 | 1235.15 |
19 Dec 2024 | 1255.4 | 1240.05 | 1273.95 | 1230.95 |
18 Dec 2024 | 1247.85 | 1211 | 1256.3 | 1202.7 |
17 Dec 2024 | 1213.45 | 1246.75 | 1248.6 | 1211 |
16 Dec 2024 | 1245 | 1231.4 | 1247.95 | 1220.45 |
13 Dec 2024 | 1207.95 | 1215.15 | 1216.4 | 1173.25 |
12 Dec 2024 | 1215.15 | 1236.35 | 1236.35 | 1211 |
11 Dec 2024 | 1225.7 | 1239.65 | 1240.5 | 1224 |
10 Dec 2024 | 1238.05 | 1246.75 | 1246.75 | 1231.75 |
09 Dec 2024 | 1239.4 | 1249 | 1258.6 | 1237.35 |
Date | Price (₹) |
---|---|
20 Dec 2024 | 1240.7 |
19 Dec 2024 | 1255.4 |
18 Dec 2024 | 1247.85 |
17 Dec 2024 | 1213.45 |
16 Dec 2024 | 1245 |
13 Dec 2024 | 1207.95 |
12 Dec 2024 | 1215.15 |
11 Dec 2024 | 1225.7 |
10 Dec 2024 | 1238.05 |
09 Dec 2024 | 1239.4 |
Company Name | ISIN Code |
---|
Cipla Ltd | INE059A01026 |
Torrent Pharmaceuticals Ltd | INE685A01028 |
Sun Pharmaceuticals Industries Ltd | INE044A01036 |
Divis Laboratories Ltd | INE361B01024 |
Mankind Pharma Ltd | INE634S01028 |
Company Name | ISIN Code |
---|---|
Cipla Ltd | INE059A01026 |
Torrent Pharmaceuticals Ltd | INE685A01028 |
Sun Pharmaceuticals Industries Ltd | INE044A01036 |
Divis Laboratories Ltd | INE361B01024 |
Mankind Pharma Ltd | INE634S01028 |
Last updated time: 22 Dec 15:30 PM
Market Value
₹ 0
Asset Value
₹ 0
* All values are in Rupees
Historical Revenue of Aurobindo Pharma Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
No data available
* All values are in ₹ crore
Historical Net Profit of Aurobindo Pharma Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
No data available
* All values are in ₹ crore
Auro Pharma gets UK MHRA nod for cancer drug
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (4...
21 Dec 2024 15:20
Auro Pharma's Telangana unit gets 2 USFDA observations
The United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufactu...
18 Dec 2024 11:17
Apitoria Pharma's Unit V completes USFDA inspection
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) in...
17 Dec 2024 19:55
Aurobindo Pharma arm receives positive opinion from EMA for Zefylti
The CHMP has recommended the granting of marketing authorization for Zefylti, which is int...
14 Dec 2024 16:18
Aurobindo Pharma Ltd drops for fifth straight session
Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1...
13 Dec 2024 13:35
CuraTeQ Biologics received recommendation of a marketing authorisation for Zefylti
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Comm...
13 Dec 2024 18:31
Unlimited trading starting at just Rs. 249*